^
    3d
    Efficacy and Safety of Microneedling Combined with Topical Medications for Psoriatic Nails (ChiCTR2600116372)
    P4, N=60, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital
    New P4 trial
    |
    Zyclara (imiquimod)
    3d
    Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer (ChiCTR2500112788)
    P2, N=45, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    carboplatin • albumin-bound paclitaxel • Zyclara (imiquimod)
    4d
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    6d
    Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model. (PubMed, Medicina (Kaunas))
    Both imiquimod and gardiquimod treatment inhibited tumor growth, with gardiquimod showing an increased potency compared to imiquimod. This implies that TLR agonists like imiquimod and gardiquimod could serve as neoadjuvant, adjuvant, or complementary immunotherapeutic agents in melanoma therapy.
    Preclinical • Journal
    |
    TLR7 (Toll Like Receptor 7)
    |
    Zyclara (imiquimod)
    7d
    TeLuRide-008: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (clinicaltrials.gov)
    P2/3, N=750, Not yet recruiting, Eikon Therapeutics
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • resiquimod sulfate (EIK1001)
    8d
    Photoimmunological hydrogel vaccine creates a supportive immune niche to promote antigen cross-presentation cascade and cancer-immunity cycle progression. (PubMed, Acta Pharm Sin B)
    The model antigen ovalbumin (OVA) and toll-like receptor 7/8 agonist resiquimod (R848) were incorporated into photothermal copper sulfide nanoparticles (CuS) to construct the nanovaccine CRPO, which was subsequently encapsulated with the granulocyte-macrophage colony-stimulating factor (GM-CSF) in sodium alginate (ALG) to form the hydrogel vaccine CRPO/G@ALG...In 4T1 tumor-bearing mice, CRPO/G@ALG effectively suppressed primary and distant tumor growth and markedly reduced lung metastasis. Collectively, our findings illustrate the transformative potential of integrating ICD induction, DC recruitment, and hydrogel delivery systems, offering new avenues to advance therapeutic tumor vaccine applications.
    Journal
    |
    CSF2 (Colony stimulating factor 2)
    |
    resiquimod (STM-416)
    11d
    B3C: Basal Cell Carcinoma Chemoprevention Trial (clinicaltrials.gov)
    P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: Jan 2032 --> May 2032 | Trial primary completion date: Jan 2032 --> May 2032
    Trial completion date • Trial primary completion date
    |
    Zyclara (imiquimod)
    13d
    Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma-A Systematic Review. (PubMed, Dermatopathology (Basel))
    Immune modulation with PD-1/PD-L1 blockade, imiquimod, HPV vaccination, or OX40 stimulation enhanced effector function. The cSCC immune microenvironment reflects a balance between cytotoxic and suppressive factors. Harmonizing multimodal immune profiling and integrating spatial context with systemic immune status may advance both prognostic stratification and therapeutic design.
    Review • Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • CD69 (CD69 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
    |
    Zyclara (imiquimod)
    13d
    transcendIT-101: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=188, Terminated, Ascendis Pharma Oncology Division A/S | Active, not recruiting --> Terminated; The Sponsor made the decision to close enrollment to prioritize our efforts on TransCon IL-2 ß/g.
    Trial termination
    |
    Keytruda (pembrolizumab) • resiquimod SR (TransCon TLR7/8 Agonist)
    16d
    Limosilactobacillus reuteri alleviates psoriasis via aryl hydrocarbon receptor-mediated regulation of Interkeukin-17A. (PubMed, Int Immunopharmacol)
    NCHBL-005 and its metabolite indole-3-acetaldehyde alleviate psoriatic inflammation through modulation of the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis, thereby restoring skin immune homeostasis. This study highlights postbiotic intervention in the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis as a promising therapeutic strategy for psoriasis.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NLRC5 (NLR Family CARD Domain Containing 5) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)
    |
    Zyclara (imiquimod)
    17d
    Trial of INI-4001 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=50, Recruiting, Inimmune Corporation | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Aug 2024 --> Oct 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc)
    19d
    A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P1, N=51, Completed, UroGen Pharma Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • zalifrelimab (UGN-301) • Vesimune (imiquimod intravesical)